Avidity Partners Management LP / RARE
Avidity Partners Management LP’s Ultragenyx Pharmaceutical In Position
Does Avidity Partners Management LP own Ultragenyx Pharmaceutical In (RARE)? Not currently — the last reported position was 154.0K shares worth $6M in Q2 2025; the fund’s latest 13F (Q1 2026) no longer reports it.
Position Value
$6M
Q2 2025
Shares
154.0K
% of Portfolio
+1.12%
Quarters Held
16
position exited
Position History RARE
Reported value by quarter
| Quarter | Shares | Value | % of Portfolio |
|---|---|---|---|
| Q2 2025 | 154.0K | $6M | +1.12% |
| Q1 2025 | 322.1K | $12M | +2.22% |
| Q4 2024 | 352.0K | $15M | +1.45% |
| Q3 2024 | 752.0K | $42M | +2.13% |
| Q2 2024 | 960.0K | $39M | +1.68% |
| Q1 2024 | 933.5K | $44M | +1.41% |
| Q4 2023 | 844.5K | $40M | +1.47% |
| Q3 2023 | 544.0K | $19M | +0.78% |
| Q2 2023 | 900.7K | $42M | +1.45% |
| Q1 2023 | 2.13M | $85M | +2.83% |
| Q4 2022 | 2.99M | $139M | +3.00% |
| Q3 2022 | 2.05M | $85M | +1.73% |
| Q2 2022 | 1.48M | $88M | +2.03% |
| Q1 2022 | 869.0K | $63M | +1.31% |
| Q4 2021 | 700.0K | $59M | +1.25% |
| Q3 2021 | 455.0K | $41M | +0.91% |
Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Avidity Partners Management LP’s full portfolio or all institutional holders of RARE.